TY - JOUR
T1 - Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication
AU - Loft, Anne
AU - Alfaro, Ana Jimena
AU - Schmidt, Søren Fisker
AU - Pedersen, Felix Boel
AU - Terkelsen, Mike Krogh
AU - Puglia, Michele
AU - Chow, Kan Kau
AU - Feuchtinger, Annette
AU - Troullinaki, Maria
AU - Maida, Adriano
AU - Wolff, Gretchen
AU - Sakurai, Minako
AU - Berutti, Riccardo
AU - Üstünel, Bilgen Ekim
AU - Nawroth, Peter
AU - Ravnskjaer, Kim
AU - Diaz, Mauricio Berriel
AU - Blagoev, Blagoy
AU - Herzig, Stephan
PY - 2021/8/3
Y1 - 2021/8/3
N2 - Liver fibrosis is a strong predictor of long-term mortality in individuals with metabolic-associated fatty liver disease; yet, the mechanisms underlying the progression from the comparatively benign fatty liver state to advanced non-alcoholic steatohepatitis (NASH) and liver fibrosis are incompletely understood. Using cell-type-resolved genomics, we show that comprehensive alterations in hepatocyte genomic and transcriptional settings during NASH progression, led to a loss of hepatocyte identity. The hepatocyte reprogramming was under tight cooperative control of a network of fibrosis-activated transcription factors, as exemplified by the transcription factor Elf-3 (ELF3) and zinc finger protein GLIS2 (GLIS2). Indeed, ELF3- and GLIS2-controlled fibrosis-dependent hepatokine genes targeting disease-associated hepatic stellate cell gene programs. Thus, interconnected transcription factor networks not only promoted hepatocyte dysfunction but also directed the intra-hepatic crosstalk necessary for NASH and fibrosis progression, implying that molecular “hub-centered” targeting strategies are superior to existing mono-target approaches as currently used in NASH therapy.
AB - Liver fibrosis is a strong predictor of long-term mortality in individuals with metabolic-associated fatty liver disease; yet, the mechanisms underlying the progression from the comparatively benign fatty liver state to advanced non-alcoholic steatohepatitis (NASH) and liver fibrosis are incompletely understood. Using cell-type-resolved genomics, we show that comprehensive alterations in hepatocyte genomic and transcriptional settings during NASH progression, led to a loss of hepatocyte identity. The hepatocyte reprogramming was under tight cooperative control of a network of fibrosis-activated transcription factors, as exemplified by the transcription factor Elf-3 (ELF3) and zinc finger protein GLIS2 (GLIS2). Indeed, ELF3- and GLIS2-controlled fibrosis-dependent hepatokine genes targeting disease-associated hepatic stellate cell gene programs. Thus, interconnected transcription factor networks not only promoted hepatocyte dysfunction but also directed the intra-hepatic crosstalk necessary for NASH and fibrosis progression, implying that molecular “hub-centered” targeting strategies are superior to existing mono-target approaches as currently used in NASH therapy.
KW - Cell type-specific profiling
KW - ELF3
KW - GLIS2
KW - genomic reprogramming
KW - hepatocytes
KW - liver fibrosis
KW - metabolic-associated fatty liver disease
KW - nonalcoholic steatohepatitis
KW - transcription factor networks
U2 - 10.1016/j.cmet.2021.06.005
DO - 10.1016/j.cmet.2021.06.005
M3 - Journal article
C2 - 34237252
SN - 1550-4131
VL - 33
SP - 1685-1700.e9
JO - Cell Metabolism
JF - Cell Metabolism
IS - 8
ER -